Biogen's BG-12 the Beneficiary?
Teva, Active Down Following Laquinimod Phase III Miss
By Tom Wall
Tuesday, August 2, 2011
Active Biotech AB stock plunged 53.5 percent and partner Teva Pharmaceutical Industries Ltd.'s shares took a 6.2 percent hit Monday following their announcement that oral multiple sclerosis (MS) drug laquinimod did not achieve its primary endpoint of reducing the annualized relapse rate (ARR) in the Phase III Bravo trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.